PCSK9 and hyperlipidemia: We only evaluated the effects of the primary drug categories in hyperlipidemia treatment instead of conducting some specific analysis based on the drug dose effect, patient populations, intervention duration, etc. For example, it is not possible to provide clear recommendations for the best age and most effective treatment duration for using PCSK9 inhibitors with powerful statins to treat hyperlipidemia owing to the wide age ranges and lengthy treatment durations in these studies.